NasdaqCM - Nasdaq Real Time Price USD
Oramed Pharmaceuticals Inc. (ORMP)
As of 1:17 PM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
8/31/2021
8/31/2020
Total Revenue
--
1,340.0000
2,703.0000
2,703.0000
2,710.0000
Gross Profit
--
--
--
--
2,710.0000
Operating Expense
12,867.0000
17,109.0000
43,301.0000
26,926.0000
14,467.0000
Operating Income
-12,867.0000
-15,769.0000
-40,598.0000
-24,223.0000
-11,757.0000
Net Non Operating Interest Income Expense
18,983.0000
4,589.0000
3,564.0000
341.0000
684.0000
Other Income Expense
--
16,268.0000
-630.0000
893.0000
-438.0000
Pretax Income
22,384.0000
5,088.0000
-37,664.0000
-22,989.0000
-11,511.0000
Tax Provision
1,634.0000
--
100.0000
--
--
Net Income Common Stockholders
20,862.0000
5,525.0000
-36,561.0000
-22,238.0000
-11,511.0000
Diluted NI Available to Com Stockholders
20,862.0000
5,525.0000
-36,561.0000
-22,238.0000
-11,511.0000
Basic EPS
0.51
0.14
-0.94
-0.78
-0.56
Diluted EPS
0.51
0.14
-0.94
-0.78
-0.56
Basic Average Shares
40,692.3430
40,315.0680
38,997.6490
28,469.0680
20,532.3470
Diluted Average Shares
41,208.4630
40,566.9010
38,997.6490
28,469.0680
20,532.3470
Total Operating Income as Reported
-12,867.0000
-15,769.0000
-40,598.0000
-24,223.0000
-11,757.0000
Total Expenses
12,867.0000
17,109.0000
43,301.0000
26,926.0000
14,467.0000
Net Income from Continuing & Discontinued Operation
20,862.0000
5,525.0000
-36,561.0000
-22,238.0000
-11,511.0000
Normalized Income
5,781.5407
-10,743.0000
-36,063.3000
-23,131.0000
-11,073.0000
Interest Income
23,273.0000
8,026.0000
3,573.0000
347.0000
690.0000
Interest Expense
2,890.0000
2,037.0000
--
--
--
Net Interest Income
18,983.0000
4,589.0000
3,564.0000
341.0000
684.0000
EBIT
25,274.0000
7,125.0000
-37,664.0000
-24,223.0000
-11,757.0000
EBITDA
25,491.0000
7,321.0000
-37,606.0000
-24,146.0000
-11,750.0000
Reconciled Depreciation
217.0000
196.0000
58.0000
77.0000
7.0000
Net Income from Continuing Operation Net Minority Interest
20,862.0000
5,525.0000
-36,561.0000
-22,238.0000
-11,511.0000
Total Unusual Items Excluding Goodwill
16,268.0000
16,268.0000
-630.0000
893.0000
-438.0000
Total Unusual Items
16,268.0000
16,268.0000
-630.0000
893.0000
-438.0000
Normalized EBITDA
9,223.0000
-8,947.0000
-36,976.0000
-25,039.0000
-11,312.0000
Tax Rate for Calcs
0.0001
--
0.0002
--
--
Tax Effect of Unusual Items
1,187.5407
--
-132.3000
--
--
8/31/2020 - 5/1/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CANF Can-Fite BioPharma Ltd.
2.1503
+0.01%
BLRX BioLineRx Ltd.
0.4150
+1.22%
KROS Keros Therapeutics, Inc.
59.37
+2.29%
NGNE Neurogene Inc.
45.74
+3.93%
PLX Protalix BioTherapeutics, Inc.
1.2200
+4.27%
PPBT Purple Biotech Ltd
3.1300
-2.49%
RAPT RAPT Therapeutics, Inc.
2.3700
+11.79%
ARCT Arcturus Therapeutics Holdings Inc.
18.04
+1.75%
CGEN Compugen Ltd.
1.6800
+5.00%
ENLV Enlivex Therapeutics Ltd.
1.3601
+0.74%